Day 2 of the 71st Scientific Sessions of the American Diabetes Association kicked off today and participants in San Diego reviewed research at the intersection of basic science and hands-on therapy.
Abstracts presented today included follow-up data from the ACT NOW trial. It suggests that pioglitazone offers vascular benefits to patients with impaired glucose tolerance regardless of whether or not their metabolic risk factors show improvement.
We’ll have details on this study and more. So if you couldn’t make it to San Diego, check back as day 2 of the 71st Scientific Sessions of the American Diabetes Association unfolds.
Check back daily for our updated reports.